Logo

Third Wave to Provide Invader Technology for NIH Sponsored Study

Jan 04, 2001

NEW YORK, Jan 4 – Third Wave Technologies said Thursday it had licensed its Invader genotyping system to Fairview University Medical Center in Minneapolis for a genotyping study to be sponsored by the NIH. 

Terms of the deal were not disclosed, although Third Wave generally opts for deals that give the company rights to discoveries made using its technology.

The study will involve genotyping at least 100,000 patient samples in order to determine a connection between genetic mutations and hemochromatosis, a disease that results in abnormal iron metabolism and can cause diabetes, cardiac problems, and arthritis.

This is the largest genotyping study ever sponsored by the NIH, Third Wave and Fariview University Medical Center said in a statement.

Third Wave of Madison, Wis., is expected to announce further deals in the near future. The company has also filed to go public.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.